Vorinostat enhances the antimyeloma effects of melphalan and bortezomib - PubMed (original) (raw)

Comparative Study

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

Richard A Campbell et al. Eur J Haematol. 2010 Mar.

Abstract

Objectives: Examine the antitumor activity of the histone deacetylase inhibitor vorinostat's antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model.

Methods: RPMI8226, U266, and MM1S cells were cultured for 48 h in the presence of media, vorinostat, melphalan, or bortezomib alone, or combinations of vorinostat with melphalan or bortezomib. Cell proliferation was measured using the MTS [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfphophenyl)-2H-tetrazolium, inner salt] assay. Severe combined immunodeficient mice bearing LAGkappa-1B tumors were treated with vorinostat [30, 60, or 100 mg/kg daily for five consecutive days per week (qdx5d), 100 or 300 mg/kg daily for 2 d/wk (qdx2d)], melphalan (1, 3, or 10 mg/kg qdx1d), bortezomib (0.25 or 0.5 mg/kg qdx2d), or combinations thereof for 35 d. Tumor growth was determined via measurement of human immunoglobulin G (hIgG) levels and tumor volume.

Results and conclusions: Vorinostat enhanced the anti-MM effects of melphalan and bortezomib in vitro. Synergism was observed with vorinostat and melphalan in RPMI8226 and U266 cell lines. Vorinostat 100 mg/kg in combination with melphalan 3 mg/kg resulted in significant inhibition of tumor growth in vivo, compared with control (tumor volume P = 0.0001; hIgG P = 0.0001), single-agent vorinostat (tumor volume P = 0.0025; hIgG P = 0.0137), and single-agent melphalan (tumor volume P = 0.0043; hIgG P = 0.0426). Vorinostat also enhanced the antimyeloma effects of bortezomib in vivo. Vorinostat enhances the anti-MM activity of melphalan and bortezomib in vitro and in vivo. This study provides rationale for further evaluation of vorinostat in combination with chemotherapeutic agents and bortezomib for the treatment of MM.

PubMed Disclaimer

Cited by

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I. Xu S, et al. Leukemia. 2018 Jul;32(7):1500-1514. doi: 10.1038/s41375-018-0061-9. Epub 2018 Feb 22. Leukemia. 2018. PMID: 29535427 Free PMC article. Review.
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Hideshima T, Richardson PG, Anderson KC. Hideshima T, et al. Mol Cancer Ther. 2011 Nov;10(11):2034-42. doi: 10.1158/1535-7163.MCT-11-0433. Mol Cancer Ther. 2011. PMID: 22072815 Free PMC article. Review.
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ, Almeciga-Pinto I, Tamang D, Yang M, Jones SS, Quayle SN. North BJ, et al. PLoS One. 2017 Mar 6;12(3):e0173507. doi: 10.1371/journal.pone.0173507. eCollection 2017. PLoS One. 2017. PMID: 28264055 Free PMC article.
Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells.
Haney SL, Allen C, Varney ML, Dykstra KM, Falcone ER, Colligan SH, Hu Q, Aldridge AM, Wright DL, Wiemer AJ, Holstein SA. Haney SL, et al. Oncotarget. 2017 Jun 16;8(44):76085-76098. doi: 10.18632/oncotarget.18543. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100294 Free PMC article.
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
Andreu-Vieyra CV, Berenson JR. Andreu-Vieyra CV, et al. Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614. Ther Adv Hematol. 2014. PMID: 25469210 Free PMC article. Review.

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib - PubMed (original) (raw)